- Home
- FHI vs CNTA Comparison
FHI vs CNTA Comparison
Compare FHI & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FHI | CNTA |
|---|---|---|
| Founded | 1955 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.7B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | FHI | CNTA |
|---|---|---|
| Price | $52.06 | $23.49 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $54.20 | $38.50 |
| AVG Volume (30 Days) | 636.7K | ★ 1.6M |
| Earning Date | 01-29-2026 | 03-23-2026 |
| Dividend Yield | ★ 2.60% | N/A |
| EPS Growth | ★ 58.80 | N/A |
| EPS | ★ 5.13 | N/A |
| Revenue | ★ $1,800,663,000.00 | $15,000,000.00 |
| Revenue This Year | $9.29 | N/A |
| Revenue Next Year | $4.32 | N/A |
| P/E Ratio | $10.21 | ★ N/A |
| Revenue Growth | 10.33 | ★ 118.88 |
| 52 Week Low | $35.05 | $9.60 |
| 52 Week High | $55.13 | $30.58 |
Technical Indicators
Market Signals| Indicator | FHI | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 47.50 | 43.38 |
| Support Level | $52.12 | $23.41 |
| Resistance Level | $53.59 | $26.51 |
| Average True Range (ATR) | 1.37 | 1.42 |
| MACD | -0.16 | 0.03 |
| Stochastic Oscillator | 29.20 | 40.16 |
Price Performance
Historical ComparisonAbout FHI Federated Hermes Inc.
Federated Hermes provides asset-management services for institutional and individual investors. The firm had $843.7 billion in managed assets at the end of June 2025, composed of equity (10%), multi-asset (less than 1%), fixed-income (12%), alternative (2%), and money market (75%) funds. The firm's cash-management operations are expected to generate around 52% of Federated's revenue this year, compared with 29%, 11%, and 8%, respectively, for the equity, fixed-income, and alternatives/multi-asset/other operations. The company's products are distributed via trust banks, wealth managers, and retail broker/dealers (67% of AUM), institutional investors (26%), and international clients (7%).
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.